VBL Therapeutics Presents MOSPD2 Bi-Specific Antibody Activity and Potential Survival Benefit for Solid Tumors in Late Breaking Research Session of the AACR Virtual Annual Meeting
TEL AVIV, Israel, June 22, 2020 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) today presented a late-breaking study showing that […]